Cellares closed a $257 million Series D to expand its commercial cell therapy manufacturing services and accelerate plans for a 2027 IPO, signaling rising demand for outsourced large‑scale cell therapy production. The company aims to commercialize its automated manufacturing platform to serve cell therapy developers moving toward commercialization. The financing arrives amid a broader bioprocessing rebound: Danaher reported strength in bioprocessing and life‑science consumables, with Q4 revenue gains tied to durability in monoclonal antibody production and instrument demand. Together the financing and corporate results underline the sector’s focus on scaling manufacturing capacity and automation to meet an expanding clinical and commercial cell and gene therapy pipeline.